Evaluation and comparison of post-vaccination adverse effects among Janssen and Oxford-AstraZeneca vaccinated adult individuals in Debre Tabor Town: A cross- sectional survey in Northwest Ethiopia

Figures & data

Table 1. Socio demographic characteristics of the study participants (n = 421).

Variables	Category	N (%)
Age (in years)	<50	324 (77.0)
	>50	97 (23.0)
Sex	Male	228 (54.2)
	Female	193 (45.8)
Marital status	Single	99 (23.5)
	Married	295(70.1)
	Widowed	15 (3.6)
	Divorced	12(2.8)
Educational status	No formal education	30(7.1)
	Primary education	187 (44.4)
	Secondary education	119(28.3)
	College/University	85(20.2)
Occupation	Housewife	64 (15.2)
	Merchant	213(50.6)
	Government employee	76 (18.1)
	Private employee	22 (5.2)
	Student	44 (10.5)
	Daily laborer	2 (0.5)

Table 2. Clinical related characteristics of the study participants (n = 421).

Variables	Category	N (%)
Smoking	Yes	9(2.1)
	No	412 (97.9)
Chronic medical illness*	Yes	13 (3.8)
	No	405 (96.2)
Allergy history**	Yes	17 (4.0)
	No	404(96.0)
BMI (in kg/m2)	<25	310 (73.6)
	undefined	111 (26.4)
History of COVID 19 infection	Yes	39(9.3)
	No	382 (90.7)

*Hypertension, diabetes mellitus, kidney disease, cancer, cardiac illness; **Food allergy, drug allergy, inhalant or other allergies.

Figure 1. The occurrence of adverse effects after vaccination with Janssen and Astra Zeneca vaccines. Significantly higher occurrence of side effects (p-value <.01) was seen in the AstraZeneca vaccine than Janssen vaccine.

Table 3. Post vaccination adverse symptoms among recipients of the Janssen and AstraZeneca vaccines.

Symptoms	Total (n = 421), n (%)	Vaccine type		p-value
		Janssen (n = 211), n (%)	AstraZeneca (n = 210), n (%)
Fever	175 (41.6%)	71(33.7%)	104(41.6%)	.001*
Fatigue	151 (35.9%)	73 (34.6%)	78(37.1%)	.657
Chills	116(27.6%)	49(23.2%)	67 (31.9%)	.060
Headache	127(30.2%)	58(27.5%)	69 (32.9%)	.274
Arthralgia	136(32.3%)	52(24.6%)	84(40.0%)	.001*
Myalgia	131(31.1%)	61(28.9%)	70(33.3%)	.381
Diarrhea	4(1.0%)	2(1.0%)	2(1.0%)	.996
Arm numbness	24(5.7%)	11(5.2%)	13(6.2%)	.824
Cough	19(4.5%)	7(3.3%)	12(5.7%)	.342
Shortness of breath	6(1.4%)	4(1.9%)	2(1.0%)	.685
Sore throat	9(2.1%)	4(1.9%)	5(2.4%)	.994
Nausea/vomiting	41(9.7%)	23(10.9%)	18(8.6%)	.521
Skin rash	3(0.7%)	1(0.5%)	2(1.0%)	.996
Injection site pain	193(45.8%)	84(39.8%)	109(51.9%)	.017*
Injection site swelling	74(17.6%)	31(14.7%)	43(20.5%)	.152
Smell or taste loss	7(1.7%)	4(1.9%)	3(1.4%)	1.000
Blood clotting	0 (0.0%)	0 (0.0%)	0 (0.0%)	–
Severe allergic reaction	0 (0.0%)	0 (0.0%)	0 (0.0%)	–

*Comparison between the two vaccines was made using the Chi-square or Fisher’s Exact test as appropriate and p-value <.05 was considered as statistically significant.

Table 4. Comparison of post-vaccination adverse symptoms and related parameters between Janssen and AstraZeneca vaccinated participants.

Variables		All participants (n = 421)
		Janssen vaccinated (n = 211)	AstraZeneca vaccinated (n = 210)	p-value*
Total number of side effects, mean$\pm$SD		4.2 $\pm$ 3.1	6.7 $\pm$ 4.6	.023
Onset of symptoms in hours, mean$\pm$SD		11.1 $\pm$ 8.3	10.7 $\pm$ 7.2	.412
Duration of symptom in days, median (IQR)		3(6)	2(7)	.062
Severity of symptoms (n = 319), n (%)	Mild (n = 198)	86 (61.0%)	112(62.9%)	.057
	Moderate (n = 110)	51 (36.2)	59 (33.1%)
	Severe (n = 11)	4 (2.8%)	7(3.9%)
Require hospitalization (n = 319), n (%)		1(0.7%)	2 (1.1%)	1.000
Require treatment (n = 319), n (%)		9(6.4%)	12 (6.7%)	.657

*Comparisons were made using independent sample t-test, Mann-Whitney test, Chi-square test, or Fisher’s exact test as appropriate. P-value <.05 was considered statistically significant. Abbreviations: IQR, interquartile range; SD, Standard deviation.

Table 5. Predictors of the mean total number of post-vaccination symptoms of the study participant.

Variables		Mean total number of side effects
		Adjusted β (95%CI)	P-value
Age (in years)	<50	0.21 (0.15, 7.71)	0.009*
	undefined	Refer.
Sex	Male	Refer.	0.023*
	Female	0.19 (0.11, 5.52)
Marital status	Married	−0.12 (−0.35, 0.11)	0.817
	Unmarried**	Refer.
Education	No education	Refer.	0.971
	$\ge$Primary education	0.02 (- 0.52, 0.16)
Smoking	Yes	−0.15 (−0.43, 0.52)	0.379
	No	Refer.
BMI (kg/m2)	<25	Refer.	0.041*
	$\ge 25$	−0.16 (−0.09, −0.89)
Chronic disease	Yes	0.01 (- 0.52, 0.16)	0.499
	No	Refer.
Allergy history	Yes	−0.04 (- 0.78, 0.55)	0.621
	No	Refer.
Prior COVID 19	Yes	−0.27 (−0.14, −1.90)	0.012*
	No	Refer.
Type of vaccine	Janssen	Refer.	0.001*
	AstraZeneca	0.31(0.19, 2.69)
Vaccine doses	One dose	Refer.	0.514
	Two doses or more	0.01(−0.27, 0.51)

*P-value <.05; ***Single, divorced, & widowed; Refer.=reference.